Vertex Pharmaceuticals Incorporated
VRTX
$433.21
$3.610.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.09B | 11.02B | 10.63B | 10.34B | 10.19B |
| Total Other Revenue | 10.00M | -- | -- | -- | -- |
| Total Revenue | 11.10B | 11.02B | 10.63B | 10.34B | 10.19B |
| Cost of Revenue | 5.21B | 5.00B | 4.93B | 4.79B | 4.55B |
| Gross Profit | 5.89B | 6.02B | 5.69B | 5.55B | 5.64B |
| SG&A Expenses | 1.49B | 1.43B | 1.46B | 1.35B | 1.24B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.69B | 6.43B | 6.39B | 6.14B | 5.79B |
| Operating Income | 4.41B | 4.59B | 4.24B | 4.20B | 4.40B |
| Income Before Tax | -300.20M | 248.50M | 259.60M | 214.70M | 4.77B |
| Income Tax Expenses | 688.70M | 784.10M | 739.40M | 704.60M | 748.00M |
| Earnings from Continuing Operations | -988.90 | -535.60 | -479.80 | -489.90 | 4.02K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -988.90M | -535.60M | -479.80M | -489.90M | 4.02B |
| EBIT | 4.41B | 4.59B | 4.24B | 4.20B | 4.40B |
| EBITDA | 4.58B | 4.77B | 4.45B | 4.39B | 4.58B |
| EPS Basic | -3.81 | -2.07 | -1.85 | -1.89 | 15.58 |
| Normalized Basic EPS | 11.82 | 12.32 | 11.58 | 11.59 | 12.05 |
| EPS Diluted | -3.92 | -2.20 | -2.00 | -2.04 | 15.41 |
| Normalized Diluted EPS | 11.72 | 12.21 | 11.48 | 11.49 | 11.92 |
| Average Basic Shares Outstanding | 1.03B | 1.03B | 1.03B | 1.03B | 1.03B |
| Average Diluted Shares Outstanding | 1.04B | 1.04B | 1.04B | 1.04B | 1.04B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |